Despite these possible confinements, intriguing data from murine steatohepatitis have given proof of the generic feasibility and efficacy of CCL2 antagonism by small molecules in combating liver diseases (Baeck et al., 2012), Clinical trials involving CCR2 antagonists in non-liver disease entities are already at hand. The gene discussed is CCR2; the disease is liver disorder.